<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80769">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02120547</url>
  </required_header>
  <id_info>
    <org_study_id>TBR 652-1-121</org_study_id>
    <nct_id>NCT02120547</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment</brief_title>
  <official_title>An Open Label, Phase 1 Study to Evaluate the Effect of Mile and Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Cenicriviroc (CVC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tobira Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tobira Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether CVC exposures are altered in subjects with impaired hepatic function,
      compared to subjects with normal hepatic function. The results will help guide the clinical
      use of CVC in patients with hepatic impairment, determine the extent of PK changes, if any,
      and identify the potential need for dose adjustments of CVC in this population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Multiple-dose pharmacokinetics of CVC</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours postdose on Days 1 and 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>Intensive PK on Days 1 and 14. Trough PK on Days 3-13. Additional free (unbound) CVC will be assessed 2 hours and 24 hours postdose on Day 14.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Days 1 through 35 for hepatic impaired subjects and Days 1-28 for healthy matching subjects</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events, concomitant medications, vital signs, 12-lead triplicate ECGs, clinical laboratory tests (chemistry, hematology, urinalysis) and physical examinations will be assessed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pro-inflammatory cytokines and biomarkers of bacterial translocation</measure>
    <time_frame>28 days after receiving first dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Liver Insufficiency</condition>
  <arm_group>
    <arm_group_label>Cenicriviroc in mild liver impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with mild liver impaired will receive cenicriviroc, 1 tablet once daily, for 14 days. Matching healthy subjects will receive Cenicriviroc, 1 tablet once daily, for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cenicriviroc in moderate liver impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with moderate liver impaired will receive cenicriviroc, 1 tablet once daily, for 14 days. Matching healthy subjects will receive Cenicriviroc, 1 tablet once daily, for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cenicriviroc in mild liver impaired</intervention_name>
    <description>Subjects with mild hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.</description>
    <arm_group_label>Cenicriviroc in mild liver impaired</arm_group_label>
    <other_name>CVC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cenicriviroc in moderate liver impaired</intervention_name>
    <description>Subjects with moderate hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.</description>
    <arm_group_label>Cenicriviroc in moderate liver impaired</arm_group_label>
    <other_name>CVC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and non-pregnant, non-lactating females aged 18-65

          -  Weight ≥ 50.0 kg

          -  BMI 18.0 - 40.0 kg/m2

          -  Able to participate, and willing to give written informed consent and to comply with
             the study restrictions

          -  Subjects with hepatic impairment will have stable liver disease (Child Pugh A or
             Child Pugh B)

        Exclusion Criteria:

          -  Pregnant or lactating women and male partners of women who are pregnant or lactating

          -  Uncontrolled treated or untreated hypertension (systolic blood pressure ≥ 160 mmHg
             and/or diastolic blood pressure ≥ 105 mmHg)

          -  QTcF &gt; 450 msec for males and &gt; 470 msec for females at Screening or Day -1

          -  Donation or loss of blood over 350 mL within 60 days prior to screening

          -  Any evidence of progressive liver disease within the last 4 weeks for subjects with
             hepatic impairment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth C Lasseter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology of Miami, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Lefebvre, MD</last_name>
    <phone>650-351-5073</phone>
    <email>elefebvre@tobiratherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Dilzer, RN</last_name>
      <phone>305-817-2900</phone>
      <phone_ext>218</phone_ext>
      <email>sdilzer@clinpharmmiami.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>April 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Insufficiency</keyword>
  <keyword>Hepatic impairment</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
